SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.
Key Details
- 1TumorSight Risk analyzes routine breast MRI, pathology, and clinical data.
- 2Provides 5- and 10-year individualized recurrence risk for HR+, HER2-negative Stage 1–3A breast cancer.
- 3World's first AI-based MRI prognostic tool for breast cancer recurrence risk, per SimBioSys.
- 4FDA clearance announced October 15 after a study with 2,129 patients.
- 5Risk scoring (0-100) categorizes patients as high, intermediate, or low risk.
- 6No additional procedures or specialized hardware are required to use the software.
Why It Matters
The FDA clearance of TumorSight Risk represents a major advancement for precision oncology, enabling more objective and personalized breast cancer treatment planning using existing imaging data. This paves the way for broader clinical integration of AI in radiologic cancer prognostics.
Source
Radiology Business
Related News
•Radiology Business
Webinar to Showcase Successful AI Automation in Radiology Workflows
A webinar will provide insights from imaging leaders on expanding and optimizing AI-driven automation in radiology clinical workflows.
•AuntMinnie
AI Quantitative MRI and Amyloid PET Used for ARIA Monitoring in Alzheimer's
AI-driven MRI analysis complements Amyloid PET in detecting ARIA during Alzheimer's treatment.
•AuntMinnie
Radiomics Features Vary Between Manual and AI-Driven Segmentations
DL-based segmentations on CT and MRI show limited agreement and bias compared to manual segmentations, affecting radiomics model reliability.